{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T07:06:59Z","timestamp":1771657619940,"version":"3.50.1"},"reference-count":37,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T00:00:00Z","timestamp":1671148800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007200","name":"Medizinische Fakult\u00e4t, Ruhr-Universit\u00e4t Bochum","doi-asserted-by":"publisher","award":["F1009-2021"],"award-info":[{"award-number":["F1009-2021"]}],"id":[{"id":"10.13039\/501100007200","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Seroprevalence studies can contribute to a better assessment of the actual incidence of infection. Since long-term data for Germany are lacking, we determined the seroprevalence of immunoglobulin G (IgG) antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in residual plasma samples of 3,759 German regular blood donors between July 2020 and June 2021. Over almost the entire study period, the incidences determined based on our data were higher than those officially reported by the Robert Koch Institute, the public health institute in Germany. Using our serological testing strategy, we retrospectively detected natural infection in 206\/3,759 (5.48%; 95% confidence interval (CI): 4.77\u20136.25) individuals. The IgG seroprevalence ranked from 5.15% (95% CI: 3.73\u20136.89) in Lower Saxony to 5.62% (95% CI: 4.57\u20136.84) in North Rhine Westphalia. The analyses of follow-up samples of 88 seropositive blood donors revealed a comparable fast decay of binding and neutralizing anti-SARS-CoV-2 IgG antibodies. The antibody avidity remained at a low level throughout the whole follow-up period of up to 181 days. Interestingly, female donors seem to express a stronger and longer lasting humoral immunity against the new coronavirus when compared to males. <jats:bold>Conclusion:<\/jats:bold> Overall, our data emphasizes that seroprevalence measurements can and should be used to understand the true incidence of infection better. Further characterization of follow-up samples from seropositive donors indicated rapid antibody waning with sex-specific differences concerning the strength and persistence of humoral immune response.<\/jats:p>","DOI":"10.1371\/journal.pone.0279195","type":"journal-article","created":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T18:27:00Z","timestamp":1671215220000},"page":"e0279195","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["Analysis of a German blood donor cohort reveals a high number of undetected SARS-CoV-2 infections and sex-specific differences in humoral immune response"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0763-5522","authenticated-orcid":true,"given":"Bastian","family":"Fischer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cornelius","family":"Knabbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanja","family":"Vollmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2022,12,16]]},"reference":[{"issue":"2","key":"pone.0279195.ref001","first-page":"E311","article-title":"Case fatality rate of COVID-19: a systematic review and meta-analysis","volume":"62","author":"Y Alimohamadi","year":"2021","journal-title":"J Prev Med Hyg"},{"issue":"1","key":"pone.0279195.ref002","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bsheal.2020.09.003","article-title":"Estimation of the case fatality rate of COVID-19 epidemiological data in Nigeria using statistical regression analysis","volume":"3","author":"AA Suleiman","year":"2021","journal-title":"Biosaf Health"},{"issue":"1","key":"pone.0279195.ref003","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s15010-020-01509-1","article-title":"Risk factors for Covid-19 severity and fatality: a structured literature review","volume":"49","author":"D Wolff","year":"2021","journal-title":"Infection"},{"issue":"1","key":"pone.0279195.ref004","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12890-021-01455-0","article-title":"Covid-19 and gender: lower rate but same mortality of severe disease in women-an observational study","volume":"21","author":"F Raimondi","year":"2021","journal-title":"BMC Pulm Med"},{"issue":"10265","key":"pone.0279195.ref005","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1016\/S0140-6736(20)32350-3","article-title":"The UK needs a sustainable strategy for COVID-19","volume":"396","author":"D Gurdasani","year":"2020","journal-title":"The Lancet"},{"issue":"6","key":"pone.0279195.ref006","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1007\/s15010-021-01713-7","article-title":"Effectiveness of extended shutdown measures during the \u00b4Bundesnotbremse\u00b4 introduced in the third SARS-CoV-2 wave in Germany","volume":"49","author":"A Schuppert","year":"2021","journal-title":"Infection"},{"key":"pone.0279195.ref007","doi-asserted-by":"crossref","first-page":"100151","DOI":"10.1016\/j.lanepe.2021.100151","article-title":"Different spreading dynamics throughout Germany during the second wave of the COVID-19 pandemic: a time series study based on national surveillance data","volume":"6","author":"A Schuppert","year":"2021","journal-title":"Lancet Reg Health Eur"},{"issue":"5","key":"pone.0279195.ref008","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.healthpol.2021.03.013","article-title":"COVID-19 vaccine challenges: What have we learned so far and what remains to be done?","volume":"125","author":"R Forman","year":"2021","journal-title":"Health Policy"},{"issue":"13","key":"pone.0279195.ref009","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph18136688","article-title":"COVID-19 Vaccination: Status and Willingness to Be Vaccinated among Employees in Health and Welfare Care in Germany","volume":"18","author":"A Kozak","year":"2021","journal-title":"Int J Environ Res Public Health"},{"issue":"34","key":"pone.0279195.ref010","article-title":"Asymptomatic SARS-CoV-2 infection: A systematic review and meta-analysis","volume":"118","author":"P Sah","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"pone.0279195.ref011","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1080\/22221751.2020.1729071","article-title":"Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes","volume":"9","author":"W Zhang","year":"2020","journal-title":"Emerg Microbes Infect"},{"issue":"4","key":"pone.0279195.ref012","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s00284-022-02800-0","article-title":"Long-Term Persistence of Anti-SARS-COV-2 IgG Antibodies","volume":"79","author":"Z Yousefi","year":"2022","journal-title":"Curr Microbiol"},{"issue":"6","key":"pone.0279195.ref013","doi-asserted-by":"crossref","first-page":"811","DOI":"10.7326\/M20-7547","article-title":"Antibody Response After SARS-CoV-2 Infection and Implications for Immunity: A Rapid Living Review","volume":"174","author":"I Arkhipova-Jenkins","year":"2021","journal-title":"Ann Intern Med"},{"issue":"1","key":"pone.0279195.ref014","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s41541-021-00396-3","article-title":"Distinct SARS-CoV-2 antibody reactivity patterns elicited by natural infection and mRNA vaccination","volume":"6","author":"R Assis","year":"2021","journal-title":"NPJ Vaccines"},{"issue":"28","key":"pone.0279195.ref015","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2020.25.28.2001285","article-title":"SARS-CoV-2 IgG seroprevalence in blood donors located in three different federal states, Germany, March to June 2020","volume":"25","author":"B Fischer","year":"2020","journal-title":"Euro Surveill"},{"key":"pone.0279195.ref016","journal-title":"Robert Koch Institut Erfassung der SARS-CoV-2-Testzahlen in Deutschland"},{"key":"pone.0279195.ref017","doi-asserted-by":"crossref","first-page":"198114","DOI":"10.1016\/j.virusres.2020.198114","article-title":"COVID-19 Vaccine: A comprehensive status report","volume":"288","author":"SP Kaur","year":"2020","journal-title":"Virus Res"},{"issue":"3","key":"pone.0279195.ref018","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/ina.12766","article-title":"Indoor transmission of SARS-CoV-2","volume":"31","author":"H Qian","year":"2021","journal-title":"Indoor Air"},{"key":"pone.0279195.ref019","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jpeds.2021.09.013","article-title":"Viewpoint of the European Pediatric Societies over Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccination in Children Younger Than Age 12 Years Amid Return to School and the Surging Virus Variants","volume":"239","author":"M Pettoello-Mantovani","year":"2021","journal-title":"J Pediatr"},{"key":"pone.0279195.ref020","doi-asserted-by":"crossref","first-page":"100252","DOI":"10.1016\/j.lanepe.2021.100252","article-title":"Household transmission of COVID-19 cases associated with SARS-CoV-2 delta variant (B.1.617.2): national case-control study","volume":"12","author":"H Allen","year":"2022","journal-title":"Lancet Reg Health Eur"},{"key":"pone.0279195.ref021","article-title":"Comparative transmissibility of SARS-CoV-2 variants Delta and Alpha in New England, USA","author":"R Earnest","year":"2021","journal-title":"medRxiv"},{"issue":"Suppl 4","key":"pone.0279195.ref022","first-page":"2","article-title":"German and international studies on SARS-CoV-2 seroprevalence","volume":"5","author":"C Poethko-M\u00fcller","year":"2020","journal-title":"J Health Monit"},{"issue":"48","key":"pone.0279195.ref023","first-page":"824","article-title":"SARS-CoV-2 Seroprevalence in Germany: A Population-Based Sequential Study in Seven Regions","volume":"118","author":"D Gornyk","year":"2021","journal-title":"Dtsch Arztebl Int"},{"key":"pone.0279195.ref024","volume-title":"Bundeszentrale f\u00fcr politische Bildung Bundesl\u00e4nder\u2013Bev\u00f6lkerung"},{"issue":"12","key":"pone.0279195.ref025","doi-asserted-by":"crossref","first-page":"e0242398","DOI":"10.1371\/journal.pone.0242398","article-title":"Spreading of COVID-19: Density matters","volume":"15","author":"DWS Wong","year":"2020","journal-title":"PLoS One"},{"issue":"30","key":"pone.0279195.ref026","doi-asserted-by":"crossref","first-page":"40424","DOI":"10.1007\/s11356-021-12364-4","article-title":"Association between population density and infection rate suggests the importance of social distancing and travel restriction in reducing the COVID-19 pandemic","volume":"28","author":"H Yin","year":"2021","journal-title":"Environ Sci Pollut Res Int"},{"issue":"11","key":"pone.0279195.ref027","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1056\/NEJMc2025179","article-title":"Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19","volume":"383","author":"FJ Ibarrondo","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"pone.0279195.ref028","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1515\/cclm-2020-1347","article-title":"Sustained SARS-CoV-2 nucleocapsid antibody levels in nonsevere COVID-19: a population-based study","volume":"59","author":"A Schaffner","year":"2020","journal-title":"Clin Chem Lab Med"},{"issue":"6","key":"pone.0279195.ref029","doi-asserted-by":"crossref","first-page":"e240","DOI":"10.1016\/S2666-5247(21)00025-2","article-title":"Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study","volume":"2","author":"WN Chia","year":"2021","journal-title":"The Lancet Microbe"},{"issue":"1","key":"pone.0279195.ref030","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1038\/s41467-021-22958-8","article-title":"Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival","volume":"12","author":"S Dispinseri","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"pone.0279195.ref031","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1038\/s41598-022-06629-2","article-title":"mRNA vaccine-induced antibodies more effective than natural immunity in neutralizing SARS-CoV-2 and its high affinity variants","volume":"12","author":"Y Yu","year":"2022","journal-title":"Sci Rep"},{"issue":"3","key":"pone.0279195.ref032","doi-asserted-by":"crossref","DOI":"10.3390\/v14030617","article-title":"Avidity of IgG to SARS-CoV-2 RBD as a Prognostic Factor for the Severity of COVID-19 Reinfection","volume":"14","author":"V Manuylov","year":"2022","journal-title":"Viruses"},{"issue":"4","key":"pone.0279195.ref033","doi-asserted-by":"crossref","DOI":"10.3390\/v14040758","article-title":"Characterizing Kinetics and Avidity of SARS-CoV-2 Antibody Responses in COVID-19 Greek Patients","volume":"14","author":"S Labropoulou","year":"2022","journal-title":"Viruses"},{"issue":"12","key":"pone.0279195.ref034","doi-asserted-by":"crossref","first-page":"6765","DOI":"10.1002\/jmv.27270","article-title":"Vaccination versus infection with SARS-CoV-2: Establishment of a high avidity IgG response versus incomplete avidity maturation","volume":"93","author":"F Struck","year":"2021","journal-title":"J Med Virol"},{"issue":"10","key":"pone.0279195.ref035","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1002\/jmv.25989","article-title":"A comparison study of SARS-CoV-2 IgG antibody between male and female COVID-19 patients: A possible reason underlying different outcome between sex","volume":"92","author":"F Zeng","year":"2020","journal-title":"J Med Virol"},{"issue":"7837","key":"pone.0279195.ref036","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41586-020-2700-3","article-title":"Sex differences in immune responses that underlie COVID-19 disease outcomes","volume":"588","author":"T Takahashi","year":"2020","journal-title":"Nature"},{"issue":"4","key":"pone.0279195.ref037","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1001\/jamainternmed.2020.7976","article-title":"Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020","volume":"181","author":"KL Bajema","year":"2021","journal-title":"JAMA Intern Med"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0279195","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T18:27:29Z","timestamp":1671215249000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0279195"}},"subtitle":[],"editor":[{"given":"Luisa","family":"Gregori","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,12,16]]},"references-count":37,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0279195","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,16]]}}}